Another phase 2b study of tralokinumab showed a nonsignificant reduction of the asthma exacerbation rates, and somewhat encouraging results were observed in a subgroup of patients with higher baseline levels of dipeptidyl peptidase (DPP)-4 and periostin [8]. Here, DPP4 is linked to asthma.